UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000050236
Receipt number R000057207
Scientific Title An Observational Study of Changes in Nutritional Status in Patients with Liver Cirrhosis after Treatment for Decreased Appetite with Rikkunshito
Date of disclosure of the study information 2023/03/01
Last modified on 2024/02/16 17:38:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Does improvement of appetite with Rikkunshito improve the nutritional status of patients with liver cirrhosis?

Acronym

Rikkunshito study

Scientific Title

An Observational Study of Changes in Nutritional Status in Patients with Liver Cirrhosis after Treatment for Decreased Appetite with Rikkunshito

Scientific Title:Acronym

Observational study after treatment for decreased appetite

Region

Japan


Condition

Condition

Liver cirrhosis with decreased appetite

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Clarify the course of patients with cirrhosis after improvement of appetite.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum albumin level 12 weeks after the start of Rikkunshito treatment.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Liver cirrhosis patient with loss of appetite receiving treatment with Rikkunshito

Key exclusion criteria

1. Patients under 19 years old and over 80 years old
2. Patients with cancer
3. Pregnant and lactating patients
4. Patients with poorly controlled ascites
5. Patients with poorly controlled hepatic encephalopathy
6. Patients with severely impaired renal function (eGFR<30 ml/min/1.73m2)
7. Patients who have indicated their refusal to participate in the study
8. Patients with alcohol dependence
9. Dementia (PS2 or higher)
10. Patients with psychiatric disorders who are regularly attending or being hospitalized by a neuropsychiatrist and who are considered to have difficulty participating in the study
11. Other patients who are judged to be ineligible by the investigators and subinvestigators
12. Patients with other addictions
13. Patients with intellectual disability
14. Patients with cerebral organic mental disorder

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Tatsuichi
Middle name
Last name An

Organization

Bellland General Hospital

Division name

Department of Hepatology and Gastroenterology

Zip code

599-8247

Address

500-3 Higashiyama, Naka-ku, Sakai City, Osaka, Japan

TEL

072-234-2001

Email

t_an@seichokai.or.jp


Public contact

Name of contact person

1st name Yosuke
Middle name
Last name Aihara

Organization

Bellland General Hospital

Division name

Department of Hepatology and Gastroenterology

Zip code

599-8247

Address

500-3 Higashiyama, Naka-ku, Sakai City, Osaka, Japan

TEL

072-234-2001

Homepage URL


Email

y_aihara@seichokai.or.jp


Sponsor or person

Institute

Bellland General Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Bellland General Hospital

Address

500-3 Higashiyama, Naka-ku, Sakai City, Osaka, Japan

Tel

072-234-2001

Email

irb@bh.seichokai.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 03 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 03 Month 01 Day

Date of IRB

2023 Year 02 Month 09 Day

Anticipated trial start date

2023 Year 03 Month 01 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Single arm
Ovservation study
Pilot study


Management information

Registered date

2023 Year 02 Month 05 Day

Last modified on

2024 Year 02 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057207


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name